Share this Article
Singh VA, Haseeb A, Alkubaisi AA
Correspondence: Dr Vivek Ajit Singh, drvivek69@gmail.com
ABSTRACT
INTRODUCTION Morbidity and mortality from malignant diseases are usually the result of metastasis. The bone is the third most common site of metastasis.
METHODS This is a retrospective study of patients with metastatic bone disease who were referred to the Orthopaedic Department of University Malaya Medical Centre, Malaysia, between January 2004 and October 2009.
RESULTS A total of 151 patients (51.0% men, 49.0% women) had metastatic bone disease, with the highest incidence at the age range of 50–59 years. The commonest primary cancer was breast (23.3%), followed by lung (21.2%), prostate (9.3%), thyroid (7.3%) and renal cell carcinoma (5.3%); unknown primary cancer was 6.6%. There was long bone involvement in 52.7% of cases, axial bone in 44.5%, and both long and axial bones in 2.8%. The majority (90.1%) were symptomatic, with pain as the commonest symptom. 106 (70.2%) patients had pathological fractures. Neurological deficit was reported in 90.7% of patients, with 41.1% having extraskeletal metastases. 67.8% of the lesions were osteolytic, 24.3% were sclerotic, and 7.9%, mixed. Palliative and therapeutic interventions were undertaken for 62.0% of patients. The mean survival times were: breast 21.0; thyroid 20.7; prostate 20.3; lung 16.0; and unknown primary cancer 32.6 months.
CONCLUSION In our study, breast and lung cancers were the commonest primary cancers in metastatic bone disease. Most patients had more than one site of involvement, pain at presentation and pathological fractures. Surgery is beneficial to relieve pain and improve function and neurology. Duration of survival depends on the type of primary cancer and whether systemic metastasis is present.
Keywords: bone, metastasis, outcome, survival
Singapore Med J 2014; 55(10): 539-546; http://dx.doi.org/10.11622/smedj.2014138
REFERENCES
| 1. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001; 27:165-76. http://dx.doi.org/10.1053/ctrv.2000.0210 | ||||
| 2. Nielsen OS, Munro AJ, Tannock IF. Bone metastases: pathophysiology and management policy. J Clin Oncol 1991; 9:509-24. PMid:1705581 | ||||
| 3. Schaberg J, Gainor BJ. A profile of metastatic carcinoma of the spine. Spine (Phila Pa 1976) 1985; 10:19-20. http://dx.doi.org/10.1097/00007632-198501000-00003 | ||||
| 4. Mirels H. Metastatic disease in long bones. A proposed scoring system for diagnosingimpending pathologic fractures. Clin Orthop Relat Res 1989; 256-64. PMid:2684463 | ||||
| 5. American Cancer Society. Cancer-related pain: A guide for patients and caregivers. http://www.cancer.org/acs/groups/content/documents/document/acspc-030531.... Accessed October 13, 2014. | ||||
| 6. Frankel HL, Hancock DO, Hyslop G, et al. The value of posturalreduction in the initial management of close injuries of the spine with paraplegia and tetraplegia. Paraplegia 1969; 7:179-92. http://dx.doi.org/10.1038/sc.1969.30 | ||||
| 7. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006; 12:6243s-9s. http://dx.doi.org/10.1158/1078-0432.CCR-06-0931 | ||||
| 8. Harrington KD. Impending pathologic fractures from metastatic malignancy: evaluation and management. Instr Course Lect 1986; 35:357?81. PMid:3819423 | ||||
| 9. Sundaresan N, DiGiacinto GV, Krol G, Hughes JE. Spondylectomy for malignant tumors of the spine. J Clin Oncol 1989; 7:1485-91. PMid:2778479 | ||||
| 10. Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain 1997; 69:1-18. http://dx.doi.org/10.1016/S0304-3959(96)03267-8 | ||||
| 11. Selvaggi G, Scagliotti GV. Management of bone metastases in cancer: a review.Crit Rev Oncol Hematol 2005; 56:365-78. http://dx.doi.org/10.1016/j.critrevonc.2005.03.011 | ||||
| 12. Chow E, Hoskin P, van der Linden Y, Bottomley A, Velikova G. Quality of life and symptom end points in palliative bone metastases trials. Clin Oncol (R Coll Radiol) 2006; 18:67-9. http://dx.doi.org/10.1016/j.clon.2005.06.016 | ||||
| 13. Mercadante S, Arcuri E. Breakthrough pain in cancer patients: pathophysiology and treatment. Cancer Treat Rev 1998; 24:425-32. http://dx.doi.org/10.1016/S0305-7372(98)90005-6 | ||||
| 14. Portenoy RK, Lesage P. Management of cancer pain. Lancet 1999; 353:1695-700. http://dx.doi.org/10.1016/S0140-6736(99)01310-0 | ||||
| 15. Banning A, Sjøgren P, Henriksen H. Pain causes in 200 patients referred to a multidisciplinary cancer pain clinic. Pain 1991; 45:45-8. http://dx.doi.org/10.1016/0304-3959(91)90163-R | ||||
| 16. Coleman RE. How can we improve the treatment of bone metastases further? Curr Opin Oncol 1998; 10 Suppl 1:S7-13. PMid:9801853 | ||||
| 17. Coleman RE, Houston S, Purohit OP, et al. A randomised phase II study of oral pamidronate for the treatment of bone metastases from breast cancer. Eur J Cancer 1998; 34:820-4. http://dx.doi.org/10.1016/S0959-8049(97)10155-1 | ||||
| 18. Tillman RM. The role of the orthopaedic surgeon in metastatic disease of the appendicular skeleton.Working Party on Metastatic Bone Disease in Breast Cancer in the UK. J Bone Joint Surg Br 1999; 81:1-2. http://dx.doi.org/10.1302/0301-620X.81B1.9514 | ||||
| 19. Kunisada T, Choong PF. Major reconstruction for periacetabular metastasis: early complications and outcome following surgical treatment in 40 hips. Acta Orthop Scand 2000; 71:585-90. http://dx.doi.org/10.1080/000164700317362217 | ||||
| 20. Posner JB, Howieson J, Cvitkovic E. "Disappearing" spinal cord compression: oncolytic effect of glucocorticoids (and other chemotherapeutic agents) on epidural metastases. Ann Neurol 1977; 2:409-13. http://dx.doi.org/10.1002/ana.410020511 | ||||
| 21. Gabriel K, Schiff D. Metastatic spinal cord compression by solid tumors. Semin Neurol 2004; 24:375-83. http://dx.doi.org/10.1055/s-2004-861532 | ||||
| 22. Tatsui H, Onomura T, MorishitaS, Oketa M, Inoue T. Survival rates of patients with metastatic spinal cancer after scintigraphic detection of abnormal radioactive accumulation. Spine (Phila Pa 1976) 1996; 21:2143?8. | ||||
| 23. Tsuya A, Kurata T, Tamura K, Fukuoka M. Skeletal metastases in non-small cell lung cancer: a retrospective study. Lung Cancer 2007; 57:229-32. http://dx.doi.org/10.1016/j.lungcan.2007.03.013 | ||||
| 24. Paterson AH, Powles TJ, Kanis JA, et al. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993; 11:59-65. PMid:8418243 | ||||
| 25. Koenders PG, Beex LV, Kloppenborg PW, Smals AG, Benraad TJ. Human breast cancer: survival from first metastasis. Breast Cancer Study Group. Breast Cancer Res Treat 1992; 21:173-80. http://dx.doi.org/10.1007/BF01975000 | ||||
| 26. Saad F, Karakiewicz P, Perrotte P. The role of bisphosphonates in hormone-refractory prostate cancer. World J Urol 2005; 23:14-8. http://dx.doi.org/10.1007/s00345-004-0472-2 | ||||
| 27. Pittas AG, Adler M, Fazzari M, et al. Bone metastases from thyroid carcinoma: clinical characteristics and prognostic variables in one hundred forty-six patients. Thyroid 2000; 10:261-8. http://dx.doi.org/10.1089/thy.2000.10.261 | ||||
| 28. Pavlidis N, Fizazi K. Cancer of unknown primary (CUP). Crit Rev Oncol Hematol 2005; 54:243-50. http://dx.doi.org/10.1016/j.critrevonc.2004.10.002 | ||||
| 29. Krementz ET, Cerise EJ, Foster DS, Morgan LR Jr. Metastases of undetermined source. Curr Probl Cancer 1979; 4:4-37. http://dx.doi.org/10.1016/S0147-0272(79)80019-7 | ||||
| 30. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non–small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009; 27:4247-53. http://dx.doi.org/10.1200/JCO.2009.22.6993 | ||||
| 31. Toyoda Y, Shinohara N, Harabayashi T, et al. Survival and prognostic classification of patients with metastatic renal cell carcinoma of bone. Eur Urol 2007; 52:163-8. http://dx.doi.org/10.1016/j.eururo.2006.10.060 | ||||
| 32. Tomita K, Kawahara N, Kobayashi T, et al. Surgical strategy for spinal metastases. Spine (Phila Pa 1976) 2001; 26:298-306. http://dx.doi.org/10.1097/00007632-200102010-00016 | ||||
| 33. Kuru B, Camlibel M, Dinc S, et al. Prognostic factors for survival in breast cancer patients who developed distant metastasis subsequent to definitive surgery. Singapore Med J 2008; 49:904-11. PMid:19037557 | ||||
| 34. Swenerton KD, Legha SS, Smith T, et al. Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res 1979; 39:1552-62. PMid:427797 | ||||
| 35. Brown JE, Cook RJ, Major P, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005; 97:59-69. http://dx.doi.org/10.1093/jnci/dji002 | ||||